FY2027 EPS Estimate for Journey Medical Decreased by Analyst

Journey Medical Co. (NASDAQ:DERM) – Equities researchers at B. Riley decreased their FY2027 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company will earn $0.31 per share for the year, down from their previous forecast of $0.39. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The business had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.21 million.

Separately, Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.67.

Journey Medical Trading Up 3.2 %

Journey Medical stock opened at $6.11 on Monday. The business has a 50 day moving average price of $5.09 and a two-hundred day moving average price of $5.17. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a 12 month low of $3.20 and a 12 month high of $6.89. The stock has a market cap of $127.64 million, a price-to-earnings ratio of -6.50 and a beta of 0.97.

Insider Activity

In related news, CEO Claude Maraoui sold 23,508 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52. Following the completion of the transaction, the chief executive officer now owns 2,139,922 shares in the company, valued at $11,106,195.18. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 105,831 shares of company stock worth $536,622. Corporate insiders own 13.16% of the company’s stock.

Institutional Trading of Journey Medical

A number of large investors have recently bought and sold shares of DERM. Cetera Investment Advisers boosted its stake in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares in the last quarter. PVG Asset Management Corp lifted its holdings in Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after purchasing an additional 9,005 shares during the last quarter. Kovitz Investment Group Partners LLC bought a new position in Journey Medical during the 3rd quarter valued at about $66,000. Geode Capital Management LLC boosted its position in Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after buying an additional 12,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Journey Medical during the fourth quarter worth about $80,000. 7.25% of the stock is currently owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.